Naltrexone is not detected in preweaning rats following transplacental exposure: Implications for growth modulation

Life Sciences

Volumn 62, Issue 3, 1997, Pages 221-228

  Zagon, Ian S ^a,b   Jeffrey Hurst, W ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Brain; Heart; Naltrexone; Opioid antagonist; Reversed phase HPLC; Transplacental

Indexed keywords

BRAIN EXTRACT; HEART MUSCLE EXTRACT; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG TISSUE LEVEL; FEMALE; FETUS; HEART; MALE; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; POSTNATAL GROWTH; PRENATAL DRUG EXPOSURE; QUANTITATIVE ASSAY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALIA;

EID: 0031565962     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01090-4     Document Type: Article

References (33)

1. H. AKIL, S.J. WATSON, E. YOUNG, M.E. LEWIS, H. KHATCHATURIAN, J.M. WALKER, Annu. Rev. Neurosci. 7 223-255 (1984).
2. A.J. MURGO, J. Natl. Cancer Inst. 75 341-344 (1985).
3. P.M. VILLIGER, M. LOTZ, EMBO J. 11 135-143 (1992).
4. S.D. MERINEY, M.J. FORD, D. OLIVA, G. PILAR, J. Neurosci. 11 3705-3717 (1991).
5. J.V. BARTOLOME, M.B. BARTOLOME, B.A. LORBER, S.J. DILEO, S.M. SCHANBERG, Neurosci. 40 289-294 (1991).
6. J. BARG, M. BELCHEVA, R. MCHALE, R. LEVEY, Z. VOGEL, C.J. COSCIA, J. Neurochem. 60 765-767 (1993).
7. T. ISAYAMA, P.J. MCLAUGHLIN, I.S. ZAGON, Brain Res. 544 79-86 (1991).
8. I.S. ZAGON, Y. WU, P.J. MCLAUGHLIN, Amer. J. Physiol. 270 R22-R32 (1996).
9. P.J. MCLAUGHLIN, Amer. J. Physiol. 271 R122-R129 (1996).
10. I.S. ZAGON, P.J. MCLAUGHLIN, Science 221 1179-1180 (1983).
11. I.S. ZAGON, P.J. MCLAUGHLIN, Science 221 671-673 (1983).
12. I.S. ZAGON, J.W. SASSANI, E.R. KANE, P.J. MCLAUGHLIN, Brain Res. 759:92-102 (1997).
13. I.S. ZAGON, P.J. MCLAUGHLIN, Brain Res. 490 14-25 (1989).
14. I.S. ZAGON, P.J. MCLAUGHLIN, Brain Res. 542 318-323 (1991).
15. I.S. ZAGON, S.D. HYTREK, P.J. MCLAUGHLIN, Amer. J. Physiol. 271 R511-R518 (1996).
16. F.R. D'AMATO, C. CASTELLANO, M. AMMASSARI-TEULE, A. OLIVERIO, Develop. Psychobiol. 21 283-292 (1988).
17. O.B. WARD, E.P. MONAGHAN, I.L. WARD, Pharmacol. Biochem. Behav. 25 573-576 (1986).
18. G.J. HARRY, J.A. ROSECRANS, Pharmacol. Biochem. Behav. 11 (Suppl.) 19-22 (1979).
19. J. HETTA, L. TERENIUS, Neurosci. Letts. 16 323-327 (1980).
20. G.I. KESHET, M. WEINSTOCK, Pharmacol. Biochem. Behav. 50 413-419 (1995).
21. P.J. MCLAUGHLIN, S.W. TOBIAS, C.M. LANG, I.S. ZAGON, Physiol. Behav. 62: 501-508 (1997).
22. P.J. MCLAUGHLIN, S.W. TOBIAS, C.M. LANG, I.S. ZAGON, Pharmacol. Biochem. Behav. 58:1-8 (1997).
23. H. MONDER, N. YASUKAWA, J.J. CHRISTIAN, Pharmacol. Biochem. Behav. 11 235-237 (1979).
24. N.A. SHEPANEK, R.F. SMITH, L.A. ANDERSON, C.N. MEDICI, Pharmacol. Biochem. Behav. 50 313-319 (1995).
25. C.V. VORHEES, Neurobehav. Toxicol. Teratol. 3 295-301 (1981).
26. P.J. MCLAUGHLIN, Life Sci. 54 1423-1431 (1994).
27. E. COHEN, G. KESHET, Y. SHAVIT, M. WEINSTOCK, Pharmacol. Biochem. Behav. 54183-189 (1996).
28. I.S. ZAGON, S.W. TOBIAS, S.D. HYTREK, P.J. MCLAUGHLIN. Pharmacol. Biochem. Behav., in press.
29. I.S. ZAGON, W.J. HURST, P.J. MCLAUGHLIN. Life Sci. 61: 1261-1267 (1997).
30. T. ISAYAMA, W.J. HURST, P.J. MCLAUGHLIN, I.S. ZAGON, Vis. Neurosci. 12 939-950 (1995).
31. I.S. ZAGON, D.M. GIBO, P.J. MCLAUGHLIN, Brain Res. 596 149-156 (1992).
32. I.S. ZAGON, P.J. MCLAUGHLIN, Life Sci. 35: 2057-2064 (1984).
33. A.L MISRA, R. BLOCH, J. VARDY, S.J. MULE, K. VEREBELY, Drug Metab. Disp. 4:276-280 (1976).